New strategies in the treatment of acute myelogenous leukemia: Mobilization and transplantation of autologous peripheral blood stem cells in adult patients

Stem Cells

Volumn 18, Issue 5, 2000, Pages 343-351

  Bruserud, Øystein ^a   Tjønnfjord, Geir ^b   Gjertsen, Bjørn Tore ^a   Foss, Brynjar ^a   Ernst, Peter ^a  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Acute myelogenous leukemia; Autologous bone marrow transplantation; Minimal residual disease; Peripheral blood stem cell

Indexed keywords

AMSACRINE; BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IDARUBICIN; INTERLEUKIN 3; MITOXANTRONE; STEM CELL FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CELL CULTURE; CELL MOTILITY; CRYOPRESERVATION; FLOW CYTOMETRY; HUMAN; HYPERTHERMIC THERAPY; LEUKEMIA REMISSION; MINIMAL RESIDUAL DISEASE; NEUROTOXICITY; PERIPHERAL BLOOD STEM CELL; PHOTOCHEMISTRY; RELAPSE; STEM CELL TRANSPLANTATION;

ADULT; CLINICAL TRIALS; COMBINED MODALITY THERAPY; CYTARABINE; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; TRANSPLANTATION, AUTOLOGOUS;

ARA;

EID: 0033830630     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (74)

1. Acute myeloid leukemia
2. Intensive postremission chemotherapy in adults with acute myeloid leukemia
3. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia
4. Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: Results of an age-adjusted prospective randomized comparison
5. Randomised comparison of addition of autologous transplantation to intensive chemotherapy for acute myeloid leukemia in first remission: Results of MRC AML 10 trial
6. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia
7. Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia
8. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission
9. Cytarabine and neurologic toxicity
10. Peripheral blood stem cell mobilization for high-dose chemotherapy
11. Peripheral blood stem cell (PBSC) mobilization with chemotherapy followed by sequential IL3 and G-CSF administration in extensively pretreated patients
12. Increased numbers of long-term initiating cells in the apheresis product of patients randomized to receive increasing doses of stem cell factor administered in combination with chemotherapy and a standard dose of granulocyte colony-stimulating factor
13. Expression of the c-kit receptor (CD117) is a feature of almost all subtypes of de novo acute myeloblastic leukemia (AML), including cytogenetically good-risk AML, and lacks prognostic significance
14. Effects of interleukin 10 on blast cells derived from patients with acute myelogenous leukemia
15. Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia
16. A double-blind controlled study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia
17. A controlled study of recombinant granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia
18. A randomized double-blind placebo-controlled phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia
19. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: A study of the Eastern Cooperative Oncology Group (E1490)
20. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia
21. Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: A randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group
22. A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients
23. GM-CSF in a double-blind randomized placebo-controlled trial in therapy of adult patients with de novo acute myeloid leukemia (AML)
24. Recombinant human interleukin-3 (rh-IL3) in combination with remission induction chemotherapy in patients with relapsed acute myelogenous leukemia
25. Use of peripheral blood stem cells for autologous transplantation in acute myeloid leukemia allows faster engraftment and equivalent disease-free survival compared with bone marrow
26. Peripheral blood progenitor transplantation as an alternative to autologous marrow transplantation in the treatment of acute myeloid leukemia
27. Autologous peripheral blood stem cell transplantation for acute leukemias
28. Autologous peripheral blood stem cell transplantation (PBSCT) mobilized with G-CSF in AML in first complete remission. Role of intensification therapy in outcome
29. Significance of quantitative analysis of AML1/ETO transcripts in peripheral blood stem cells from t(8;21) acute myelogenous leukemia
30. Successful collection of peripheral blood progenitor cells in patients with acute myeloid leukemia following early consolidation therapy with granulocyte colony-stimulating factor-supported high-dose cytarabine and mitoxantrone
31. Collection of peripheral blood stem cells mobilized by high-dose Ara-C plus VP-16 or aclarubicin followed by recombinant human granulocyte colony-stimulating factor
32. Autologous peripheral blood progenitor cell transplantation mobilized with high-dose cytarabine in acute myeloid leukemia in first complete remission
33. Transplantation of autologous peripheral blood progenitor cells procured after high-dose cytarabine-based consolidation chemotherapy for adults with secondary acute myelogenous leukemia in first remission
34. Autologous stem cell transplantation for acute myeloid leukemia in first remission
35. Factors which affect the CFU-GM content of the peripheral blood haematopoietic progenitor cell harvests in patients with acute myeloid leukemia
36. Detection of minimal residual disease in acute myeloid leukemia: Methodologies, clinical and biological significance
37. Clinical applicability of the evaluation of minimal residual disease in acute leukemia
38. The presence of typical and atypical bcr-abl fusion genes in leukocytes of normal individuals: Biological significance and implications for the assessment of minimal residual disease
39. Detection of bcr-abl gene expression at a very low level in blood cells of some healthy individuals
40. Clonal populations of hematopoietic progenitor cells with paroxysmal nocturnal hemoglobinuria genotype and phenotype are present in normal individuals
41. Leukemia arising out of paroxysmal nocturnal hemoglobinuria
42. Creation of human tumour cells with defined genetic elements
43. Progression of colorectal cancer is associated with multiple tumor suppressor gene defects but inhibition is accomplished by correction of any single defect via chromosome transfer
44. Reversal of malignant phenotype by an anti-ras ribozyme
45. The incidence of acute promyelocytic leukemia appears constant over most of a human lifespan, implying only one rate-limiting step
46. Persistence of multipotent progenitors expressing AML1/ETO transcripts in long-term remission patients with t(8;21) acute myelogenous leukemia
47. Acute myelogenous leukemia blasts as accessory cells during T lymphocyte activation: Possible implications for future therapeutic strategies
48. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the clinical advisory comittee meeting - Airlie House, Virginia, November 1997
49. Early detection of relapse by prospective reverse transcriptase polymerase chain reaction analysis of the PML-RARA fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter AIDA trial
50. RT-PCR method with increased sensitivity shows persistence of PML-RARA fusion transcripts in patients with long-term remission of APL
51. Molecular quantitation of minimal residual disease in acute myeloid leukemia with t(8;21) can identify patients in durable remission and predict clinical relapse
52. Evaluation of minimal residual disease using reverse-transcription polymerase chain reaction in t(8;21) acute myeloid leukemia: A multicenter study of 51 patients
53. Detection of CBFB/MYH11 transcripts in patients with inversion and other abnormalities of chromosome 16 at presentation and remission
54. Prolonged molecular remission after PML/RARα-positive autologous peripheral blood stem cell transplantation in acute promyelocytic leukemia: Is relevant pretransplant minimal residual disease in the graft?
55. Detection of minimal residual disease in acute leukemia by flow cytometry
56. Immunopheno-typical detection of minimal residual disease in acute leukemia
57. Transplant characteristics: Minimal residual disease and impaired megakaryocytic colony growth as sensitive parameters for predicting relapse in acute myeloid leukemia
58. Gene-marking to trace origin of relapse after autologous bone marrow transplantation
59. Primitive hematopoietic progenitors within mobilized blood are spared by uncontrolled rate freezing
60. Reconstitution of hematopoietic system with autologous marrow taken during relapse of acute myeloblastic leukaemia and grown in long-term culture
61. Short-term liquid marrow cultures are supported by a mixture of haematopoietic cytokines but do not purge for acute myeloid or lymphoid marrow cells
62. Telomerase activity and telomere length in acute and chronic leukemia, pre- and post-ex vivo culture
63. Resveratrol selectively inhibits leukemia cells: A prospective agent for ex vivo bone marrow purging
64. Pharmacological purging of minimal residual disease from peripheral blood stem cell collections of acute myeloblastic leukemia patients: Preclinical studies
65. Effect of a vitamin D3 analog, EB1089, on hematopoietic stem cells from normal and myeloid leukemic blasts
66. Enhanced selectivity of hyperthermic purging of human progenitor cells using Goralatide, an inhibitor of cell cycle progression
67. Effect of molecular structure on the performance of triarylmethane dyes as therapeutic agents for photodynamic purging of autologous bone marrow grafts from residual tumors
68. Bone marrow purging by photodynamic treatment in children with acute leukemia. Cytoprotective action of amifostine
69. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell
70. -
71. Lack of expression of Thy-1 (CD90) on acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo
72. Autologous stem cell transplantation as postremission therapy in adult acute myelogenous leukemia; does the platelet contamination of peripheral blood mobilized stem cell grafts influence the risk of leukemia relapse?
73. Immunoregulatory cytokines in bone marrow and peripheral blood stem cell products
74. Comparison of monocyte-dependent T cell inhibitory activity in GM-CSF vs G-CSF mobilized PBSC products